Abstract: Approximately 15%~20% of patients with metastatic breast cancer have HER2-positive disease, which isassociated with more aggressive disease biology and historically, a poorer prognosis relative to other molecular subtypes. The application of trastuzumab has greatly improved patients outcomes,however, trastuzumab-resistance is common. We presented a HER-2 positive metastatic breast cancer case, who was diagnosed as primary trastuzumab resistance and successfully treated with inetetamab combined with pyrotinib and eribulin.

Key words: inetetamab, pyrotinib, trastuzumab-resistance, HER2 positive breast cancer

摘要： HER2阳性乳腺癌约占所有乳腺癌的15%~20%,其侵袭性强且预后较差。曲妥珠单抗的应用显著改善了患者的预后,但仍有部分患者会出现曲妥珠单抗耐药。本文报道一例应用“伊尼妥单抗”联合“吡咯替尼”及“艾立布林”后疗效显著的曲妥珠单抗原发耐药的晚期乳腺癌患者。

关键词: 伊尼妥单抗, 吡咯替尼, 曲妥珠单抗耐药, HER2阳性乳腺癌